NASDAQ:AAPG Ascentage Pharma Group International (AAPG) Stock Price, News & Analysis $47.90 +0.21 (+0.44%) As of 03:32 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Ascentage Pharma Group International Stock (NASDAQ:AAPG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AAPG alerts:Sign Up Key Stats Today's Range$47.20▼$48.4550-Day Range$31.51▼$47.6952-Week Range$16.50▼$48.45Volume6,948 shsAverage Volume40,304 shsMarket Capitalization$4.45 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China. Read More Receive AAPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascentage Pharma Group International and its competitors with MarketBeat's FREE daily newsletter. Email Address AAPG Stock News HeadlinesASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business UpdatesAugust 21 at 8:19 AM | finanznachrichten.deAscentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business UpdatesAugust 20 at 7:57 PM | globenewswire.comOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol quietly prints $1 million in fees every single day.August 22 at 2:00 AM | Crypto 101 Media (Ad)Ascentage Pharma’s Lisaftoclax Phase III Trial for HR-MDS Cleared by FDA and EMAAugust 18, 2025 | msn.comAscentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMAAugust 17, 2025 | globenewswire.comJ.P. Morgan Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)August 12, 2025 | theglobeandmail.comAscentage Pharma to Announce 2025 Interim Results and Corporate UpdateAugust 12, 2025 | theglobeandmail.comAscentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025August 7, 2025 | globenewswire.comSee More Headlines AAPG Stock Analysis - Frequently Asked Questions How have AAPG shares performed this year? Ascentage Pharma Group International's stock was trading at $18.67 at the beginning of 2025. Since then, AAPG shares have increased by 156.6% and is now trading at $47.90. When did Ascentage Pharma Group International IPO? Ascentage Pharma Group International (AAPG) raised $126 million in an initial public offering on Friday, January 24th 2025. The company issued 7,325,000 shares at a price of $17.25 per share. When did Ascentage Pharma Group International's lock-up period expire? Ascentage Pharma Group International's lock-up period expired on Wednesday, July 23rd. Ascentage Pharma Group International had issued 7,325,000 shares in its IPO on January 24th. The total size of the offering was $126,356,250 based on an initial share price of $17.25. Since the expiration of Ascentage Pharma Group International's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted. Who are Ascentage Pharma Group International's major shareholders? Top institutional investors of Ascentage Pharma Group International include Tema Etfs LLC (0.02%), Hsbc Holdings PLC (0.01%) and Chevy Chase Trust Holdings LLC (0.01%). How do I buy shares of Ascentage Pharma Group International? Shares of AAPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AAPG Previous SymbolNASDAQ:AAPG CIK2023311 WebN/A Phone86 512 8555 7777FaxN/AEmployees600Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio3.24 Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$134.35 million Price / Sales33.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.48 per share Price / Book99.35Miscellaneous Outstanding Shares92,960,000Free FloatN/AMarket Cap$4.43 billion OptionableN/A BetaN/A 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:AAPG) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle, Microsoft, IBM… every major AI player will be forced to secure massive amounts of this material just t...True Market Insiders | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascentage Pharma Group International - Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascentage Pharma Group International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.